Senior investigator and professor of biostatistics Diana Miglioretti, PhD, is committed to improving health care by building the evidence base for personalized cancer screening. To achieve this goal, Dr. Miglioretti pursues a rigorous combination of applied and methodological research. Her work focuses on the benefits and risks of cancer screening and appropriate use of screening and diagnostic tools including medical imaging.
Dr. Miglioretti co-leads the Breast Cancer Surveillance Consortium (BCSC)—a network of breast imaging registries that has the largest and most comprehensive collection of breast cancer screening data in the nation. Established in 1994, the BCSC is currently supported by a $17 million program project grant from the National Cancer Institute. The vast BCSC database includes information on about 12 million film, digital, and 3D mammograms for more than 2.4 million women. The BCSC also has extensive data on newer methods such as digital breast tomosynthesis (also called 3D mammography) and breast MRI (magnetic resonance imaging).
Dr. Miglioretti’s expertise in maximizing the value of the BCSC data includes establishing and evaluating data collection, helping individual sites and outside researchers with analyses, and developing new statistical techniques. In part through her efforts, results from BCSC studies have helped guide national breast cancer screening policy decisions and clinical guidelines. A few examples of Dr. Miglioretti’s BCSC studies are:
Other examples of Dr. Miglioretti’s research include:
In addition to her KPWHRI faculty position, Dr. Miglioretti is the Dean’s Professor of Biostatistics in the Department of Public Health Sciences, School of Medicine, University of California, Davis. She enthusiastically shares her expertise as an instructor at the Radiological Society of North America's (RSNA) annual workshop in clinical trials methodology, which prepares radiologists to develop clinical research protocols and apply for funding.
Among Dr. Miglioretti’s professional memberships are the American Association for Cancer Research, the International Biometrics Society Eastern and Western North America regions, and the American Statistical Association, for which she was elected a fellow.
Clustered and longitudinal data analysis; latent variable modeling; assessment of diagnostic and screening tests
Biostatistics; breast cancer screening and surveillance; mammographic breast density; risk prediction
Imaging trends; radiation exposure from medical imaging; evaluation of imaging tests
Demb J, Chu P, Nelson T, Hall D, Seibert A, Lamba R, Boone J, Krishnam M, Cagnon C, Bostani M, Gould R, Miglioretti D, Smith-Bindman R. Optimizing radiation doses for computed tomography across institutions: dose auditing and best practices. JAMA Intern Med. 2017 Apr 10. doi: 10.1001/jamainternmed.2017.0445. [Epub ahead of print].
Sprague BL, Arao RF, Miglioretti DL, Henderson LM, Buist DS, Onega T, Rauscher GH, Lee JM, Tosteson AN, Kerlikowske K, Lehman CD; Breast Cancer Surveillance Consortium. National performance benchmarks for modern diagnostic digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology. 2017 Apr;283(1):59-69. doi: 10.1148/radiol.2017161519. Epub 2017 Feb 28. PubMed
Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K. Population-attributable risk proportion of clinical risk factors for breast cancer. JJAMA Oncol. 2017 Sep 1;3(9):1228-1236. doi: 10.1001/jamaoncol.2016.6326. PubMed
Engmann NJ, Scott C, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh A, Malkov S, Whaley DH, Hruska C, Wu FF, Winham S, Miglioretti DL, Norman AD, Heine J, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomarkers Prev. 2017 Feb 1. pii: cebp.0882.2016. doi: 10.1158/1055-9965.EPI-16-0882. [Epub ahead of print]. PubMed
Ahern TP, Sprague BL, Bissell MC, Miglioretti DL, Buist DS, Braithwaite D, Kerlikowske K. Family history of breast cancer, breast density, and breast cancer risk in a U.S. breast cancer screening population. Cancer Epidemiol Biomarkers Prev. 2017 Jan 17. pii: cebp.0801.2016. doi: 10.1158/1055-9965.EPI-16-0801. [Epub ahead of print]. PubMed
Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL. Risk factors that increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst. 2016 Dec 31;109(5). pii: djw276. doi: 10.1093/jnci/djw276. Print 2017. PubMed
Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, Henderson LM, Onega T, Tosteson AN, Rauscher GH, Miglioretti DL. National performance benchmarks for modern screening digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology. 2017 Apr;283(1):49-58. doi: 10.1148/radiol.2016161174. Epub 2016 Dec 5. PubMed
Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: collaborative modeling of screening outcomes. Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23. PubMed
Miglioretti DL, Lee CI. Radiation-induced breast cancer. Ann Intern Med. 2016;165(6):452. doi: 10.7326/L16-0364. PubMed
Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 2016 Sep 8. doi: 10.1001/jamaoncol.2016.3022. [Epub ahead of print]. PubMed
Dr. Diana Buist and team reflect on HOME trial showing 50 percent screening boost in underscreened women.
Interdisciplinary group shows that home-based HPV tests can boost cervical cancer screening for women at high risk.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.
Family history sparks interest for KPWHRI senior investigator, UC Davis professor, and co-leader of the BCSC.
Read it in News and Events.
Digital breast tomosynthesis reduced patient recalls with no change in cancer detection, study shows.
HealthDay, Jul 24, 2019